Teleflex Q3 revenue slightly beats estimates
Overview
US medical device maker's Q3 revenue up 0.2% yr/yr, slightly beating analyst expectations
Adjusted diluted EPS for Q3 rose to $2.63, beating consensus
Company repurchased $350 mln in stock since July 1, 2026
Outlook
Teleflex maintains 2026 pro forma adjusted constant currency revenue growth guidance at 3.5%-4.5%
Company raises 2026 adjusted diluted EPS guidance to $7.50-$7.75 from continuing operations
Teleflex lowers 2026 GAAP revenue growth guidance to 13.2%-14.2% due to foreign exchange changes
Result Drivers
SEGMENT PERFORMANCE - Vascular and Surgical units delivered mid-single-digit growth, while Interventional returned to modest growth, per CEO Jason Weidman
TARIFF REFUNDS - Q3 results benefited from $16.5 mln in IEEPA tariff refunds recognized in continuing operations
MARGIN EXPANSION - Co cited margin expansion as contributing to robust EPS growth, even when excluding tariff refunds, per CEO Jason Weidman
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $567.78 mln | $566.77 mln (11 Analysts) |
Q3 Adjusted EPS | Beat | $2.63 | $1.90 (12 Analysts) |
Q3 EPS continuing operations | $1.30 |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Teleflex Incorporated is $155.00, about 3.4% above its November 4 closing price of $149.87
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
Nov 4 - Insulet Q3 revenue beats estimates on strong Omnipod sales
Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices
Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)